Adult vaccination

2,334 views

Published on

Published in: Education
1 Comment
7 Likes
Statistics
Notes
  • For the evidence based facts and the truth on vaccines I recommend the following: How Vaccines Harm Child Brain Development - Dr Russell Blaylock MD. (Neurosurgeon)
    http://www.youtube.com/watch?v=7QBcMYqlaDs#t=417 88 minutes
    Read 'Dissolving Illusions, disease, vaccines and the forgotten history' by Dr. Suzanne Humphries to learn the truth about the history of disease http://www.dissolvingillusions.com/
    Read my power point 'Exposing the Myth of Vaccination; Essential Information You Need to Know to be Fully Informed' at http://www.slideshare.net/db61/exposing-the-myth-of-vaccination-essential-information-you-need-to-know-to-be-fully-informed-30978670
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
No Downloads
Views
Total views
2,334
On SlideShare
0
From Embeds
0
Number of Embeds
47
Actions
Shares
0
Downloads
161
Comments
1
Likes
7
Embeds 0
No embeds

No notes for slide
  • Twinrix ® is a combined hepatitis A and hepatitis B vaccine approved in 2001 by the Food and Drug Administration (FDA) for persons 18 years of age or older. Twinrix ® contains 720 EL.U. of hepatitis A antigen and 20 μg of hepatitis B surface antigen. Primary immunization consists of three doses, given on a 0-, 1-, and 6-month schedule, the same schedule as that used for single - antigen hepatitis B vaccine. Immunogenicity of the combined vaccine appears to be similar to that of the single - antigen vaccines when given separately. Twinrix ® can be used for immunization of persons 18 years of age or older who have indications for vaccination against both hepatitis A and hepatitis B, such as users of illicit injectable drugs, men who have sex with men, and persons with clotting factor disorders who receive therapeutic blood products. Formulation for children is available in many other countries. For international travel, hepatitis A vaccine is recommended for travelers to areas of high or intermediate hepatitis A endemicity (see slide 10). Hepatitis B vaccine is recommended for travelers to areas of high or intermediate hepatitis B endemicity who plan to live or work for at least 6 months in highly endemic countries (see slide 9 in hepatitis B slide set at http://www.cdc.gov/ncidod/diseases/hepatitis/slideset/hep_b/slide_9.htm).
  • Adult vaccination

    1. 1. ADULTIMMUNIZATION PRESENTER-DR.PRADEEP KATWALMODERATOR-DR. NAVEEN K. PANDEY
    2. 2. • Jenner was an English doctor, the pioneer of smallpox vaccination and the father of immunology….
    3. 3. Louis Pasteur A Vision to future of humanity“When meditating overa disease, I neverthink of finding aremedy for it, but,instead, a means ofprevention.” 3
    4. 4. Most successful medicalintervention ever developed forprevention of infectious disease IMMUNIZATION
    5. 5. CONDITION ANNUAL NO. NO. OF CASES REDUCTION OF REPORTED IN (%) IN CASES PREVACCINE 2010A AFTER CASES WIDESPREAD (AVERAGE) VACCINATIONSMALLPOX 29,005 0 100DIPHTHERIA 21,053 0 100INVASIVE 16,069 4,167C 74PNEUMOCOCCAL INFECTION:<5 YEARS OFAGEINVASIVE 63,067 44,000C 30PNEUMOCOCCAL INFECTION:ALL AGESc Data are from the CDCs Active Bacterial Core Surveillance Report;www.cdc.gov/abcs/survreports/spneu08.pdf.Source: Adapted from Roush et al., with permission.
    6. 6. • Immunization- – Immunization is the process whereby a person is made immune or resistant to an infectious disease, typically by the administration of a vaccine.• Vaccine- A vaccine is any preparation intended to produce immunity to a disease by stimulating the production of antibodies..
    7. 7. Immunizing agents1) Vaccines• Live attenuated: Bacterial: BCG, Typhoid, plague Viral : Oral polio , Yellow fever, Measles, Mumps, Rubella, Influenza• Inactivated or killed vaccines Bacterial: Typhoid, Cholera, Pertusis, Plague Viral : Rabies, Salk (Polio), Influenza , Hepatitis B, Japanese encephalitis2) Toxoids : Diphtheria, Tetanus
    8. 8. Physiological basisACQUIRED IMMUNITY– HUMORAL IMMUNITY– CELL-MEDIATED IMMUNITY
    9. 9. Antibody response after exposure
    10. 10. Central Role of Helper T Cells
    11. 11. ADJUVANTSA vaccine adjuvant is a component that potentiates theimmune responses to an antigen and/or modulates ittowards the desired immune responses.
    12. 12. Aims of immunization• Eradication – State where disease and its causal agent have been removed from natural environment• Elimination – Reduction to zero cases or reduction in indegineous sustained transmission of infection in geographical region.• Control – Reduction of illness outcomes and limitation of the disruptive impacts associated with outbreaks of disease in communities, schools, and institutions.
    13. 13. Why we need adult vaccines ?Burden of Adult Vaccine-Preventable Disease Influenza: 10-20% of US population annually 200,000 hospitalizations 36,000 deaths (average) Pneumococcal: 2,000-5000 meningitis 40,000+ bloodstream infections 150,000-300,000 pneumonia Pertussis: 1 million Cervical cancer: 10,000 Shingles: 1 million Death from vaccine-preventable diseases: 43,000
    14. 14. WHY ADULTS?The burdenVaccination gapHigh risk groupChronic medical conditions
    15. 15. Recommendation for adult immunization• ACIP(advisory committee on immunization practices)
    16. 16. Influenza vaccine
    17. 17. • 2009, update WHO199 countriesofficially reported over 482,300 laboratory confirmed cases of the influenza H1N16,071 deaths
    18. 18. • Annual vaccination• Age 6 months and older• Early autumn before influenza outbreak• Influenza A and influenza B• Influenza type/origin/isolate number/year of isolation/subtype
    19. 19. Live vaccine• Intranasal via spray• 2-49 yrs of age• Non pregnant• Has currently – Circulating Strain of influenza A and b – Cold adapted attenuated master strain• Protection >90% in young children• Don’t give antiviral drugs for 2 weeks
    20. 20. Killed vaccine• Inactivated vaccine• 6 months or older• Has influenza A and B – Previous year circulating strain – Anticipated strain circulating this year• Immunocompromised• Protection 50-80% is expected.**
    21. 21. Contraindication Egg allergy ?Pregnant women ?Gullian barre syndrome(if within 6 wks)
    22. 22. • Vaccine was found to be 33% effective in preventing total respiratory illness (influenza-like illness and clinically diagnosed pneumonia). In prevention of pneumonia alone, vaccine was 43% effective. The estimate for prevention of pneumonia rose to 55% if the period under consideration was limited to the time of peak influenza activity. Given the number of eligible homes and the cohort methodology used, the results support continuation of current policy, encouraging use of vaccine in all nursing home residents.
    23. 23. NRS- 1011/-
    24. 24. influvacA/california/7/2009(H1N1)A/perth/16/2009(H3N2)A/victoria/210/2009B/brisbrane/60/2008Per 0.5 ml
    25. 25. Pneumococcal vaccine
    26. 26. Polysaccharide-protein Polysaccharide vaccine conjugate vaccine (PPV 23) • The Difference•CONFLIICTING RESULTS T Cell independent • Infants and youngimmunity • 7,10,13 serotypeRevaccinate after 5 yrs – Invasive pneumococcal vaccine – Antibiotic resistant strain
    27. 27. Harrison figureChanges in invasive pneumococcal disease (IPD) incidence, by serotype group,among children <5 years old (first) and adults >65 years old (second), 1998–2007.*7-Valent pneumococcal conjugate vaccine (PCV7) was introduced in the UnitedStates for routine administration to infants and young children during the second halfof 2000. (Reprinted with permission from Pilishvili et al, 2010.)
    28. 28. ConclusionThe recent introduction of universal PCV vaccination in children has ledto a change in the epidemiology of IPD in adults. The incidence of IPDassociated with PCV serotypes is expected to decrease and thatassociated with other serotypes is expected to increase in adults.Despite a reduction in the incidence of IPD, vaccinating the elderly andat-risk adults with PPV23 in Germany against IPD and NBPP remains acost-effective strategy because of its broad serotype coverage.
    29. 29. RS 1857/-• Pneumo 23
    30. 30. Hepatitis B vaccination
    31. 31. BEHAVIOURALSexually active person without long-term non-monogamous relationshipPerson with more than one sexual partner during sixmonthsSeeking STI evaluationCurrent or recent IV drug userOCCUPATIONALHealthcare professionals risk of exposure toblood or potentially infectious body fluids
    32. 32. Pre-exposure prophylaxis• Included in EPI schedule• 3 IM injections (deltoid, not gluteal)• 0,1,6 months• Contains HBsAg (10 mcg) Post-exposure prophylaxis• Administer both HBIG and HB vaccine
    33. 33. Hepatitis B vaccine RS 177 PER DOSE
    34. 34. Hepatitis A virus• Behavioral: – Men who have sex with men – IV drugs users• Occupational: – Persons working with HAV-infected primates or with HAV in a research laboratory setting.• Medical: – Persons with chronic liver disease – persons who receive clotting factor concentrates.• Other: – Persons traveling to or working in countries that have high or intermediate endemicity of hepatitis A
    35. 35. COMBINED HEPATITIS A HEPATITIS B VACCINE• Approved by the FDA in United States for persons >18 years old• Contains 720 EL.U. hepatitis A antigen and 20 μg. HBsAg• Vaccination schedule: 0,1,6 months• Immunogenicity similar to single-antigen vaccines given separately• Can be used in persons > 18 years old who need vaccination against both hepatitis A and B• Formulation for children available in many other countries
    36. 36. Meningococcal Vaccine
    37. 37. Single dose is recommended -
    38. 38. • Serogroups A,C,Y W135 T cell independent Cannot be given in age less than 2 years of age Efficay C component >90% (children) Efficacy A component >95%(all age group) Duration of protection 2-5 yrs
    39. 39. Meseals Mumps Rubella
    40. 40. MMR• All adults born in 1957 or later should have documentation of 1 or more MMR vaccine• 2nd dose- 28 days after first dose• Previous diagnosis of – Meseals – Mumps – Rubella
    41. 41. MESEALS MUMPS RUBELLAOUTBREAK SETTING OUTBREAK SETTING CHILD BEARING AGEStudents of post- Students of post -If Non-pregnantsecondary school secondary school -IF immune status is not knownHealthcare facility Healthcare facilityworkers workers Upon completion and before dischargeInternational travellers International travellers
    42. 42. Human papilloma virus• Primary goal is to prevent cervical cancer• All females 11-12 yrs• Catchup vaccination 13-26 yrs• Before sexual activity• Schedule- [0-15days-6 months}• Quadrivalent (HPV4) vaccine or bivalent vaccine (HPV2)• May be administered to males aged 9 through 26 years
    43. 43. • Four strains of human papillomavirus (HPV) -- HPV-6, 11, 16, and 18
    44. 44. Tetanus Diptheria pertusis
    45. 45. Tetanus,Diphtheria & acellular Pertusis• Primary series : 3 dose 1st & 2nd dose : at least 4 wks apart 3rd dose: 6-12 months after the second. Tdap can substitute any one of the 3 doses of Td• Booster dose : every 10 yrs Tdap or Td may be used.• Tdap should replace single dose of Td in adult aged < 65 yrs.• Pregnancy: If last Td vaccine >10 yrs : Td at 2nd or 3rd trimester. If last Td vaccine <10 yrs : Td at immediate post partum period.
    46. 46. Varicella vaccination• All adults without evidence of immunity 2 doses of single-antigen varicella vaccine A second dose if received only 1 doseSpecial consideration1) close contact with persons at high risk for severe disease2)Person with high risk for exposure or transmission.
    47. 47. Herpes zooster Vaccine
    48. 48. Herpes zooster • Single dose • Adults aged 60 years and older • Regardless of whether they report a previous episode of herpes zoster Hib vaccine1 dose of Hib vaccine should be considered forpersons who have sickle cell disease, leukemia, or HIVinfection, or who have had a splenectomy
    49. 49. Our senario
    50. 50. REFRENCES• Harrisons Principles of Internal Medicine, 18th Edition• Guyton and Hall Textbook of Medical Physiology (12th Edn)• http://www.cdc.gov/vaccines/default.htm• http://www.fda.gov/BiologicsBloodVaccines /Vaccines/QuestionsaboutVaccines/ucm070 418.htm

    ×